Cite
HARVARD Citation
Lee, C. et al. (2021). Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet oncology. 22 (7), pp. 946-958. [Online].